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Abstract

There were 224,210 new cases of lung cancer in the US during 2014, and of those cases,
there 159,260 that died from lung cancer during 2014. Since early diagnosis and
treatment leads to a better prognosis, the medical community is actively looking for new,
noninvasive tests for the disease. This includes the search for new and effective tumor
markers. Tumor markers are used in combination with other tests to diagnose cancer.
After the diagnosis, they are used to follow a patient’s case. The three tumor markers
studied were neuron specific enolase (NSE), carcinoembryonic antigen (CEA), and
CYFRA 21-1. In this study, the normal reference intervals were developed using sera
from healthy donors. The analytical properties of the tumor marker assays were tested for
and found to be satisfactory. The study was designed to compare the diagnostic and
predictive values for the three tumor markers. Preliminary results on 638 patients (76
lung cancer patients, 562 healthy patients) included: (1) diagnostic % sensitivity (CEA
22.37%, NSE 0%, CYFRA 21-1 18.92%), (2) diagnostic % specificity (CEA 80.43%,
NSE 99.39%, CYFRA 21-1 93.16%), (3) %PV+ (CEA 13.39%, NSE 4.17%, CYFRA 211 28.00%), (4) %PV- (CEA 88.45%, NSE 87.12%, CYFRA 21-1 89.09%), (5)
%efficiency (CEA 73.51, NSE 86.65%, CYFRA 21-1 84.00%). It was hypothesized that
CYFRA 21-1 would be superior to CEA and NSE for the sero-diagnosis of lung cancer in
a cohort of patients, and the hypothesis was rejected. CYFRA 21-1 was not superior to
CEA and NSE in the sero-diagnosis of lung cancer.
Key Terms: Cancer, Carcinembryonic Antigen, Neuron Specific Enolase, CYFRA 21-1,
Lung Cancer
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Introduction
Epidemiology
In the US, there were 1,665,540 cases of all types of cancer in 2014 and 585,720
resulting deaths in 2014 (American Cancer Society, 2014). Since early diagnosis and
treatment leads to a better prognosis, the medical community is actively looking for new
noninvasive tests for the disease. This includes the search for new and effective tumor
markers.
Objective of Study
The objective of this study was to compare and evaluate three tumor markers,
CYFRA 21-1, carcino embryonic antigen (CEA), and neuron specific enolase (NSE) for
the sero-diagnosis of lung cancer.
The tumor marker CYFRA 21-1 is used to diagnose lung cancer, but it has also
proved successful in identifying other tumors. It can be a marker for cancers of the head
and neck. It also has proved successful in monitoring tumors in the cervix and has been
considered useful in identifying non-small cell lung cancer (NSCLC). This includes
squamous cell carcinoma (SCC), adenocarcinoma, and large cell carcinoma. These types
of tumors account for 80% of the lung tumors (Nakamura & Wu, 1997).
CEA is a marker that has been used for colorectal cancer, renal cancer, ovarian
cancer, and breast cancer. It was first discovered in extracts of colon cancer. It was
thought that a tumor specific marker had been found, but it was later discovered that not
all colon tumors produced CEA. This is because tumors are very heterogeneous in their
composition. Similarly, elevated blood CEA has been observed in heavy smokers who
were tumor free. It is used as a minor marker in lung cancer (Nakamura & Wu, 1997).
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NSE is a soluble metal-activated glycolytic metalloenzyme that provides
components necessary for aerobic glycolysis. Decreasing values of this enzyme after
primary treatment corresponding to the half-life period is the first sign of a good
prognosis and good treatment effect. NSE can play no role in the staging of the disease. It
was also found unable to differentiate between partial and complete response to treatment
(Schneider et al., 2002).
Hypothesis
It is hypothesized that CYFRA 21-1 will be superior to CEA and NSE for the
sero- diagnosis of lung cancer in a cohort of patients.
Literature Review
Cancer
History. During the past 150 years, infectious diseases have been replaced by
arterial disease and cancer as the major causes of death. Today, arterial disease accounts
for 50% of all deaths in the US, and cancer accounts for 20% of deaths in the US. Heart
attacks and strokes, which are associated with arterial disease, are seen as hazards of old
age, lack of exercise, and poor diet. Cancer, though, is thought of as an unpredictable
disease. It strikes no matter how old or how fit one is. This seems to be true because
cancer can be related to environmental factors (Conklin, 1949).
Nomenclature. A carcinogen is a substance that causes cancer. Some chemical
carcinogens can act directly, but others require metabolism in vivo before becoming
effective. Viruses are submicroscopic particles that contain either DNA or RNA. Both
DNA and RNA are long strands of four of the chemical units called nucleotides. Tumor
viruses can elicit cancerous changes in cells. Oncogenes are genes whose protein
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products may be involved in processes leading to transformation of a normal cell to a
malignant state. The gene may be known as a viral oncogene if it was detected in a
transforming virus. A tumor suppressor gene is a gene whose mutation or loss may lead
to cellular transformation and to the development of cancer. Angiogenesis is the
formation of new blood vessels. This process is essential for tumor growth and appears to
be stimulated by endothelial cell growth factors. Metastasis is the spread of cells from a
primary tumor to a noncontiguous site, usually via the bloodstream or lymphatics, and the
establishment of a secondary growth. Apoptosis is a process resulting in cell death due to
the activation of a genetic program that causes cells to lose viability before they lose
membrane integrity. The process involves endonuclease mediated cleavage of the DNA
into fragments of specific lengths leading to a "DNA ladder" when it is subjected to gel
electrophoresis. Apoptosis is also called programmed cell death and is important in
maintaining tissue homeostasis; it may be important in the response of tumor and normal
tissue cells to therapeutic agents (Bristow, Harrington, Hill, & Tannock, 2005)
Epidemiology. There were 1,638,910 new cases of cancer in the US in 2012.
Also, in 2012, there were 577,190 deaths in the US due to cancer. In 2005, seven years
earlier, the statistics for new cases and deaths from those cases were close to the same.
The number of new cases was 1,372,910, and the number of deaths out of those cases
was 570,280. Despite medical advances, the prevalence and incidence has not improved.
That is why there is such an extreme importance for studying cancer. (American Cancer
Society)
Major types of cancer. Some major types of cancer are lung, breast, colorectal,
stomach, prostate, cervical, ovarian, testicular and bladder. The tumor markers Cyfra 21-
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1 and CEA identify two or more of these major types of cancer. Cyfra 21-1 has been
reported to be elevated in patients with tumors of the lungs and in cervical cancer.
Elevated CEA has been reported with lung, breast, colorectal, stomach, prostate, and
bladder tumors. CEA is a protein found on the surface of the above listed cancers that it
identifies with and some embryonic cell types. These tumors are of epithelial cell origin
and were derived from endoderm during embryonic development. Thus, they share some
common properties (Cooper, 1992). The tumor marker NSE is associated with
neuroendocrine tumors. There will be heightened NSE antigen with carcinoid tumors,
endocrine pancreatic tumors, phenocromocytoma, medullary thyroid cancer, and
neuroblastoma (Schneider et al., 2002).
Lifestyle choices. The incidence of lung cancer in western countries is directly
proportional to the amount of cigarettes its inhabitants smoked 10 to 20 years earlier. The
amount of cigarettes smoked in the western countries is completely irrelevant to
incidence of lung cancer during that time period. The damage has to have been done to
the body years earlier than when the lung cancer occurs (Cairns, 1975).
Just as the choice to smoke cigarettes influences the chance of someone
developing lung cancer years later, a person’s occupational choice can have the same
effect. Occupational cancers are those that are due to exposure to industrial chemicals
(e.g. benzene) while working. These cancers may not appear until 10 to 20 years after the
person has retired (Cairns, 1975).
Another lifestyle choice that can have an effect is the amount of exposure to the
sun. Sunbathing can lead to skin cancer. People with fair skin are more likely to develop
skin cancer than those with darker skin. Another occupational hazard involves working
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with x-ray machines and the need to wear lead aprons. Also, they have started shooting
the x-rays from a distance. Before these safety measures were instituted, there was more
prevalence of cancer among x-ray technicians.
Chemical carcinogens. Chemical carcinogens can cause cancer. Some chemicals
are electrophiles, meaning that they are looking for an electron to become more stable.
This is the reason that they will bind to the first contacted electron donor. Carcinogens
could be in a nose cell, a lung cell, or a skin cell, where they bind to the DNA. The
polymerase then starts trying to copy the DNA but the chemical carcinogen is in the way.
The polymerase may skip that spot or move to the other side and start copying there.
Some organic chemicals, which are carcinogens, include anthracene oil, aromatic rings,
Benzol, Carbon black, Creosote, mineral oils, paraffin oil, polycyclic hydrocarbons, shale
oil, soot, tar and pitch, aniline, Azo dyes, and Estrogens (Conklin, 1949).
Viruses. Viruses are packets of genetic information encased in a protein. The
information can be embodied in either DNA or RNA (Bishop, 1982). The central dogma
of molecular biology held that information sequentially transferred from DNA to RNA to
protein. There are some viruses that have a reverse flow of information that goes from
RNA to DNA. This group of viruses that has a reverse flow of information also provides
a reverse transcriptase enzyme to synthesize cDNA (complementary DNA) from RNA.
Many of these viruses produce cancer in animals and have also been linked to
transformations in humans. These viruses are known as retroviruses. Retroviruses have
been found to infect animals such as mice, birds, minks, cats, and cows. They also infect
humans. An example of a retrovirus that infects humans is HIV. HIV has been known to
cause tumorigenesis (Richardson, 2005). This concept led to an experiment done in the
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1950’s with the rous sarcoma virus. A tissue culture assay for the rous sarcoma virus
was developed. The assay involved adding suspensions of the virus to sparse cultures of
cells taken from the body wall of chicken embryos. The virus infected some cells and
turned them into tumor cells. The transformed cells differed in morphology and in growth
properties (Temin, 1972).
The number of transformed cells was proportional to the number of infectious
units of the virus added to the cell culture. The rous sarcoma virus was different from
previous viruses studied in that it did not cause the cell that it infected to die. The cells
that were infected with this virus continued to survive and produced virus particles when
they divided (Temin, 1972). An infecting virus insinuates its genetic information into the
cellular machinery so that the cell synthesizes viral proteins specified by viral genes
(Bishop, 1982).
Oncogenes and tumor suppressor genes. Although genes implicated in the
development of cancer were first observed to work with in viruses, they are not only
found in viruses. The genes are not limited to being a part of cancer cells. They are
present, functioning, and necessary for the life of the normal cell. Oncogenes serve as the
code for proteins which contribute to cellular proliferation that is necessary for growth
and development as well as wound healing (Bishop, 1982).
An oncogene is a gene whose protein product may be involved in processes
leading to transformation of a normal cell to a malignant state. Oncogenes are the genes
that cause cancer. They are altered versions of ordinarily benign genes present in normal
cells. A normal oncogene encodes proteins. Proteins are the substances that provide the
structure of the living cell and catalyze its biochemistry. The proteins are what determine
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a cell's form and function. Once the oncogene is transformed, the proteins encoded by it
function abnormally and transform a normal cell into a cancer cell (Hunter, 1984).
A tumor suppressor gene is a gene whose mutation or loss may lead to cellular
transformation and to the development of cancer. Oncogenes are dominant, and tumor
suppressor genes are recessive. They are also known as recessive oncogenes or antioncogenes. Their inactivation can lead to a loss of function mutation. Oncogene
activation and tumor suppressor gene inactivation allow a stepwise progression of
tumorigenesis (Oster, Penn, & Stambolic, 2005).
Growth Factors, Receptors, and Signaling. In multicellular organisms, cell
regulation is controlled by polypeptide molecules called growth factors. These growth
factors interact with receptors on the cell surface, which leads to the modification of
intracellular biochemical signaling pathways that control cellular responses such as cell
proliferation. Receptors for growth factors are molecules that span the membrane of the
cell surface and have the ability to phosphorylate themselves and other cytoplasmic
proteins on tyrosine residues activating a cascade of signals. These receptor molecules
are called receptor protein tyrosine kinases. When the growth factor binds, it induces
conformational changes in the extracellular domain of the receptor that facilitates
dimerization. The dimerization results in phosphophorylation. There are some abnormal
receptor proteins. Their abnormality can be caused by denaturation, which is when a
protein is damaged by heat, and the area where the growth factor is supposed to bind is
not the right shape and size. This leads to the growth factor either not binding at all or the
wrong growth factor binding to the site. This produces continuous and inappropriate
cellular signaling, which could lead to increased cellular proliferation. This occurs
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because the signaling pathways that the receptor proteins are stimulating control cellular
proliferation (McGill & McGlade, 2005).
MicroRNAs. MicroRNAs are short non-coding RNAs of 20-24 nucleotides that
play important roles in virtually all-biological pathways in mammals. MiRNAs influence
numerous cancer relevant processes such as proliferation, cell cycle control, apoptosis,
differentiation, migration, and metabolism. A single miRNA may target up to several
hundred mRNAs and affect multiple transcripts, which influence cancer related signaling
pathways. MiRNAs have a tight integration in the cellular regulatory circuits. This can
be the downfall for a cell. The deregulation of a small subset of miRNAs may affect the
expression pattern and drive the cells toward transformation. MiRNAs are generally
down-regulated in cancer, and tumors often present reduced levels of mature miRNAs.
This is because the tumors have genetic loss, epigenetic silencing, defects in their
biogenesis pathways, and transcriptional regression. Because of miRNAs involvement in
the regulation of the cellular processes, they are a promising therapeutic tool, even
though the study has a long way to go for the full understanding of the mechanisms
(Jansson & Lund, 2012).
Radiation carcinogenesis. Humans are exposed to low levels of radiation
throughout life. These low levels of radiation have been studied and no real harm comes
from them usually. However there are certain types of radiation that have a cumulative
effect. Damage to the DNA is the most critical effect of low-level radiation. Damage to
the chromosomes is often repaired by the body, but it is sometimes misrepaired. This
results in chromosomal abnormalities. These chromosomal abnormalities can lead to
cancer because the gene now is not functioning correctly. There have been people that
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have had cancer caused by radiation therapy. The radiation is supposed to pass through
the tissues to get to the tumor to kill it and make it stop proliferating, but while doing
that, it damages the tissues around it and the tissues it passes through (Upton, 1982).
Other forms of radiation that can be harmful to some people are those that they
are involved with in their occupation. There are cancer cases among radium-dial painters,
radiologists, uranium and other miners, and nuclear workers. They are exposed to
radiation over time, and it has a cumulative effect, which can cause cancer (Upton, 1982).
Cell proliferation and tumor growth. Normal cell cycle progression is a highly
regulated series of events. There are two phases in the cell cycle called the S phase (DNA
Synthesis) and the M phase (mitosis). The gap between the M and S phase is called G1.
The gap between the S phase and the M phase is called G2. After the M phase, cells may
enter the G0 phase if there is no stimulus to further divide. Once there is a stimulus, cells
in the G0 or G1 progress to a restriction point R. In cancer cells, there is deregulation of
control mechanisms such that when the cell receives a stimulus it is more likely to
proceed through check point R. That is how tumor growth begins. During tumor
development, the cell cycle is constantly deregulated. The progression of the cancer,
which allows for the continuing development of the tumor, involves processes that abort
differentiation, allow immortalization, and promote loss of sensitivity to growth
inhibiting stimuli (Donovan, Slingerland, & Tannock, 2005).
Differentiation is the development of cells that have specific morphological and
bio-chemical characteristics that control and describe all the normal functions of a
particular tissue. In cancer cells, the processes that promote differentiation are aborted, so
the cells that develop the tumor are different from the normal tissues cells around them.
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They do not have the characteristics that promote normal function (Donovan et al.,
2005).
Normal cells do not proliferate indefinitely. They have a proliferative potential
that is constrained to a definite number of population doublings. This leads to a terminal
growth arrest or senescence. Senescence functions as a form of tumor suppression
because it will stop proliferation, limiting genetic errors in a cell. When a cell loses its
ability to stop proliferating, it becomes immortal and has uncontrolled cell proliferation
(Donovan et al., 2005).
Once the cells are proliferating uncontrollably, they have also lost the ability to be
sensitive to growth inhibiting stimuli. This means that when there are too many cells in
an area, they will not stop proliferating. The cancer cells begin to form clumps and stack
on top of each as they proliferate. That is how a tumor forms (Donovan et al., 2005).
Tumor progression and metastasis. Most patients do not die from a single
tumor. They ultimately die because of the progression of the tumor and its metastasis.
Metastasis is the spread of multiple tumor colonies that have detached themselves from
the original tumor and moved via blood and lymph to other tissues in other parts of the
body (Nicolson, 1979).
Studies have shown that cells from certain cancer types (tumors) will only travel
to certain other tissues and areas of the body. Breast carcinomas tend to spread to the
brain or lung. A study was done where the cells were injected above (upstream) and
below (downstream) the area of study. The cells would find the area they were specific to
even if they had to travel around the body to get back to it after their point of injection.
Once the cancer cells do reach the blood stream their chance of survival decreases. The
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fast movement of the bloodstream will kill some of the individual cancer cells. A study
was done in which melanoma cells were injected into the bloodstream of mice. Within a
few minutes most of the melanoma cells had died. It is very hard for the cells to survive
the fast movement and hostile environment of the blood stream (Nicolson, 1979).
Angiogenesis. Angiogenesis is the critical event that converts a self-contained
packet of cells into a group of malignant cells. The malignancy happens when the tumor
becomes vascularized. At this point the tumor has induced the host to provide it with its
own network of blood vessels. The tumor induces the host to provide these blood vessels
by releasing a chemical substance named tumor angiogenesis factor or TAF. The TAF
stimulates the nearby blood vessels to send out new capillaries that will grow toward the
tumor and eventually penetrate it. Once the tumor is vascularized it can bring in its own
nutrients through the vessels and deplete its waste as well. This is why rapid growth
follows (Folkman, 1976).
Cell death (apoptosis). Apoptosis is a process resulting in cell death due to the
activation of a genetic program that causes cells to lose viability before they lose
membrane integrity. Apoptosis is also called programmed cell death and is important in
maintaining tissue homeostasis. It may be important in the response of tumor and normal
tissue cells to therapeutic agents directed against cancer. Apoptosis is a genetically
regulated response. It can be triggered by growth factor deprivation or other DNA
damaging agents like radiation or chemotherapeutic drugs (Hakem & Harrington, 2005).
Cancer treatment.
Hormone therapy used in prostate cancer. There is now hormone therapy to
slow the growth of the hormone dependent tumors, such as in the prostate. The LHRH
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(Luteinizing Hormone Releasing Hormone) is normally released from the
hypothalamus in pulses. This leads to the pulsatile release of FSH (Follicle Stimulating
Hormone) and LH (Luteinizing Hormone). The LH attaches to the receptors on the
Leydig cells of the testes. This promotes testosterone production. Testosterone can be
converted into dihydrotestosterone. Testosterone and dihydrotestosterone will feed back
in a negative feed back loop and turn off the gonadotropin releasing hormone so that no
more LH will to stimulate the release of testosterone (Hellerstedt & Pienta, 2002).
There are methods of primary androgen ablation that helps eliminate prostate
cancer. Sometimes an agonist for LHRH is used. This will stimulate the release of
LHRH. Then testosterone will be produced and all of the androgenic receptors will be
occupied where no more testosterone is produced. This can be a problem because there is
an initial surge of testosterone. Cyproterone acetate is another treatment involved with
the hormones that make testosterone. It is a steroidal progestational antiandrogen that
blocks the androgen receptor interaction and reduces serum testosterone (Hellerstedt &
Pienta, 2002). The reduction of the testosterone will help slow the growth of the prostate
cancer.
Monoclonal antibodies. The antigens on the surface of the tumor cells are
studied. The tumor antigens that are expressed are selected for antibody targeting.
Therapy with antibodies requires a comprehensive analysis of tumor expression and
normal tissue expression so that there is understanding of the biological role of the
antigen in the tumor growth. There are several mechanisms of tumor cell killing by
antibodies. This is why the antibodies and antigens have to form a particular complex,
and this complex cannot be internalized by the cell unless a drug is being delivered to the
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tumor cell. These mechanisms of tumor cell killing by antibodies are direct cell killing
mechanisms through receptor blockade or agonist activity, induction of apoptosis, or
delivery of a drug, radiation, or cytotoxic agent. This is when the cell internalizes the
antibody-antigen complex. The mechanisms of tumor cell killing can also be through
immune-mediated cell killing mechanisms and regulation of T cell function and specific
effects on tumor vasculature and stroma (Allison, Scott, & Wolchok, 2012).
Gamma knife surgery. Gamma knife stereotactic radiosurgery was developed as
a noninvasive alternative to conventional neurosurgery. It is characterized by a single,
high-dose external radiation in mechanically fixed conditions. This system was used to
maximize the target dose exposure while minimizing undue exposure of surrounding
tissues. This technique was originally used on benign diseases an extraaxial intracranial
lesions (Gerosa, 2003).

Lung Cancer
Epidemiology. There were 224,210 new cases of lung cancer in the US during
2014, and there were 159,260 of these patients that died during 2014 (American Cancer
Society, 2014).
Common believed causes of lung cancer.
Asbestos. Asbestos is a commonly believed cause of cancer. This is not a
complete truth. Asbestos cannot cause cancer by itself. It has to have a contributing
factor like lung fibrosis. There were 839 men that were studied that were involved in the
manufacturing of asbestos containing cement. The study concluded that the men that had
lung fibrosis before the start of working there had an increased risk for having asbestos
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caused lung cancer. The men that did not have lung fibrosis were not at an increased
risk for lung cancer from working with asbestos. Lung fibrosis is caused by smoking or a
viral or bacterial infection like pneumonia that leaves dark spots on the lungs (Hughes &
Well, 1991).
Radon. Radon is another commonly believed cause of cancer. It is one of the
most extensively studied human lung carcinogens. Underground miners and their
occupational study is where most of the evidence is derived from. Underground miners
are exposed to much higher radon levels than are what are commonly found in the
household. It is clear that underground mine workers have an excess risk for lung cancer.
There are much lower doses of radon in the household which makes household exposures
being a risk for lung cancer much more unclear (Alavanha et al., 2004).
There are also major differences in the home exposures and the underground
exposures that occur in mines. These differences include the relative proportion of radon
itself to its decay products, respiratory rate, and particle size distribution. The decay
products affect the amount of energy deposited in the lung. The respiratory rate affects
the rate radon and its decay products are inhaled and retained in the lung. The particle
size distribution affects the fraction of radon progeny attached to particles and the depth
of penetration and site of deposition within the lung. This is why it is hard to compare
household radon hazard studies to occupational hazard studies of underground mine
workers (Alavanha et al., 2004).
It has been found that there is as much cellular DNA damage due to a low level
dose over an extended period of time as to a high dose of radon that the underground
mine workers receive. It can be concluded from this evidence that residential radon does
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account for some lung cancer and that 10-15% of the lung cancer cases are due to
residential radon (Alavanha et al., 2004).
Chromosome breakage. In the past ten years, the researchers in genome stability
have observed many types of cancers that are associated with chromosome breakage.
Breast cancer has been particularly studied with chromosomal breakage (Przybytkowski
et al., 2014). When chromosomes break, they normally form back together unchanged
and replication continues, and then, the cell divides. But, there are times where the break
leads to deletions or rearrangements. The genes being replicated that are in the area
where the DNA broke are now changed. Cancer cells generally have some sort of
deletion or rearrangement. This is why chromosome breakage is thought to have a
medical consequence. What if the cell, during chromosome breakage, loses part of the
gene that is needed for the cellular DNA to continue replicating properly in the break
correction? What if there was a mutation in the tumor suppressor gene during the
correction of the chromosome breakage? Now a rapidly dividing cell has occurred that
eventually will form a tumor (Tufts University, 2007).
Diagnosis and staging.
Computed tomography. Computed tomography scanning is based on the
measurement of the amount of x-ray weakening as x-rays pass through different tissues
within the body. Bone and tissues interact differently with the tomography, producing
different attenuation coefficients. Attenuation coefficients are a quantity that
characterizes how easily a material or medium can be penetrated by a beam of light.
Attenuation coefficients can be calculated as a function of the space in the cross sectional
area where the x-rays pass. These different functions of space show up on the two-
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dimensional image as different shades of grey in an area. This creates a twodimensional image and is generally used for chest x-rays and mammograms. If there is a
tumor in the lung or in breast tissue, there will be a different attenuation coefficient as
compared to that seen with normal lung and breast tissue. CT scanning is also a type of
computed tomography. CT scanning is a cross sectional image obtained by exposure to a
thin beam of x-rays throughout a 360 degree rotation. Both x-ray imaging and CT
scanning provide exclusively anatomical information (Sherar, 2005).
Nuclear Medicine and Bone Scans. Nuclear medicine uses radioactive agents to
obtain images of tumors in the patient for diagnosis. The radioactive agents are
radioactive isotopes. The radioactive isotopes used for diagnostic imaging emit highenergy photons. The photons are detected by a large sodium iodide crystal scanner, which
transfers the photons into light signals. The light signals are then detected using a
photomultiplier tube. This type of imaging is used commonly for detecting the presence
of metastatic disease to the bone (Sherar, 2005).
Magnetic resonance imaging. Magnetic resonance imaging is based on
magnetization of tissues when a patient is placed in a large, externally applied magnetic
field contained in a MRI scanner. MRIs have become a commonly used technique for the
diagnosis of cancer. MRIs have an excellent soft tissue contrast and resolution. It is
excellent for imaging the brain, head, neck, and pelvic region (Sherar, 2005).
Ultrasound. The standard B mode ultrasound is used in diagnosis. The imaging
projected from this ultrasound is based on the reflection of very high frequency sound
signals. The ultrasound uses a piezoelectric crystal that generates a short ultrasound pulse
that penetrates the tissue and is reflected by structures with different mechanical
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properties. The image the ultrasound forms is produced by time-gating the signals
scattered back to the transducer. The scattering of ultrasound is different between normal
tissues and tumors. An ultrasound is particularly useful for diagnosis in the abdomen.
However, it will not pass through bone well enough for it to provide proper imaging
(Sherar, 2005).
Treatments.
Surgery. Surgery can be curative when performed early on in the course of the
disease. That is if the tumor is operable (Nakamura & Wu, 1997).
Chemotherapy. Patients are treated commonly with chemotherapy. Many cancer
drugs are also carcinogens, and all cancer drugs are toxic to normal tissues. They cause
toxic damage through effects on DNA and DNA synthesis. Patients who are long-term
survivors of chemotherapy are at risk for a second malignant tumor because their DNA
and tissues have been damaged. Many secondary malignancies are acute leukemias.
Toxicity to the normal tissues limits both the dose and the frequency of drug
administration (Boyer & Tannock, 2005).
Methotrexate as a form of chemotherapy. Methotrexate is a powerful, versatile
drug that is used in cancer chemotherapy. It is a folic acid antagonist, so it inhibits DNA
synthesis. It is used both orally and intra-arterial infusion (Boulter, 1967). There are
acute manifestations of damage seen in multiple organs after doses of methotrexate. The
acute manifestations are first seen in the gastrointestinal tract. It will cause the
suppression of the gut epithelial cell mitosis in the crypts. This will eventually lead to
ulcers. These ulcers have also been seen in the mucous membranes and hair bulbs.
Acute and chronic pneumonitis is also a manifestation of the damage that methotrexate
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can cause. Liver damage is another side effect of the use of the drug as chemotherapy.
All in all, with high doses, most organ systems are not spared. This is because the drug
inhibits DNA synthesis (Heyn, Krivit, Nesbit, & Sharp, 1976).
Radiation. Radiotherapy involves both external beam radiotherapy and
brachytherapy. The type of radiation used depends on the type of tumor and the location
within the body. The dose depends on whether the therapy is curative or palliative, the
size of the tumor, the radiosensitivity of the tumor, and the amount of damage that can be
delivered to the surrounding normal tissue. The effects that happen to the body after
radiation happen to the organs that are in the irradiated path. The effects increase with the
volume of the tissue treated with the radiation beams (Bristow & Hill, 2005).
Conformal radiotherapy uses three dimensional treatment planning using a series
of radiation beams streaming from different angles to maximize the effect of the
treatment. The tumor is localized by MRI imaging or a CT scan before the radiotherapy is
performed. The energy and radiation beams are then chosen (Bristow & Hill, 2005).
Tumor markers. If metastases has not occurred, the patient's chance for survival
and for a cure increases greatly. Most of the time, metastases has already occurred before
the tumor is detected, so the patient's chance for a cure greatly decreases. Preventive
efforts that people use include: mammography for breast cancer, pap smears for cervical
cancer, blood detection in the stool for bowel cancer, and physical examination for
prostate cancer (Nakamura & Wu, 1997).
Tumor markers were at one time thought to be useful for detection of disease and
for early prognostic information. This was because they were shown to be increased in
the blood stream several months before symptoms showed up. The tumor marker CEA
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was used to look for a colorectal carcinoma in men. It was discovered that the tumor
markers did not have enough of a degree of specificity for screening. For example, CEA
is also found in the serum of patients with other malignant and nonmalignant illnesses
(Nakamura & Wu, 1997).
A very important way tumor markers can be used is to monitor the course of a
disease. Tumor marker levels will show whether the disease is in remission or relapsing.
Other procedures lack the sensitivity and convenience that the tumor markers have.
Tumor markers work better for monitoring the disease because one does not require the
same level of specificity as is needed in diagnosis. Tumor markers also provide the
information for choosing the best drug for treatment of the cancer (Nakamura & Wu,
1997).
Major classifications of tumor markers. A molecule that can be identified with
malignant transformation, proliferation, dedifferentiation, and metastases can be used as a
tumor marker. The value of a tumor marker is based on its specificity and sensitivity. It
has become more popular in recent years to use tumor markers to select for appropriate
treatments of tumors (Nakamura & Wu, 1997).
Some major classes of tumor markers are enzymes, isoenzymes, and proteins.
They are used today in combination with other tumor markers in multiple marker format.
Some enzymes that are used as tumor markers are ribonucleases, prostatic acid
phosphatases, and lysozymes. Ribonucleases are used to find the cancer of the pancreas,
breast, colon, liver, lung, and stomach. Phostatic acid phosphatases are used to find
prostate carcinomas at a late stage. Lysozymes are used to find colon cancer, monocytic
and myelomonocytic leukemias (Nakamura & Wu, 1997).
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Isoenzymes are another class of tumor markers. Aldolase B, type IV collagendegrading enzyme, and CK-BB are all types of isoenzyme tumor markers. Aldolase B
will show an increase when there is metastatic liver cancer. Type IV collagen-degrading
enzyme will increase when there is a detection of metastases of hepatocellular carcinoma,
and CK-BB will increase when there is an adenocarcinoma of the prostate, lung, and
stomach. CK-BB is not a very specific isoenzyme (Nakamura & Wu, 1997).
Carcinoembryonic proteins are another class of tumor markers. CEA, AFP, and
SP1 carcinoma proteins are examples of this class of tumor marker. CEA is a tumor
marker that shows up when there is cancer of the gastrointestinal tract. AFP is a
carcinoembryonic protein that increases when there are hepatoma and yolk sac tumors.
And lastly, SP1 increases when there is a trophoblastic tumor (Nakamura & Wu, 1997).
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Materials and Methods
Two of the kits used in this project for the ELISA assays carcinoembrionic antigen
(CEA) and neuron specific enolase (NSE) were acquired from Diagnostic Automation, Inc
(Calabasas, CA). The third kit for the ELISA assay CYFRA 21-1 was acquired from
Fujirebio Diagnostic, Inc (Immuno-Biological Laboratories, Inc). All the solutions that
were used were prepared from using diluents present in the kits. Tests were performed
using ELISA assays. Statistical analyses were performed using SPSS version 22 statistical
software. The samples were tested for the specific antigen at the hospitals of their origin.
Permission for this study was granted by the University of Southern Mississippi
Institutional Review Board to ensure adherence to stipulated criteria (Appendix A).
Patient sera samples were obtained from area hospitals with only a sample code
number and the cancer diagnosis provided. Normal samples from healthy subjects were
also obtained from area hospitals. All procedures protecting the confidentiality of the
patient were followed. No information regarding the identification of the patient was
released by the hospitals involved. Aseptic techniques were used at all times with the
samples. Samples were collected by hospital personnel at the respective hospitals, allowed
to clot, and were separated before being frozen and packaged in plastic tubes for transport.
Before testing, all of the samples were sorted into test tube racks and allowed to reach room
temperature by soaking in a water bath at approximately 25ºC.
Patient samples were classified by the hospital pathologists as either cancerous or
cancer free. This diagnosis was provided for comparison only (see table 1). There were
264 healthy control subjects tested for CEA. There were 200 healthy control subjects tested
for CYFRA 21-1, and there were 80 healthy control subjects tested for NSE.
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There were testing procedures followed for each assay (CEA, CYFRA 21-1, and
NSE). The results of the assays performed were read with a Beckman Coulter AD 340
(Beckman-Coulter, Brea, CA, USA) microplate reader.
Table 1
Patient Sample Classification
Number of Samples

Cancer Diagnosis

76

Cancerous

562

Cancer Free

Total number of Patients: 638

CEA ELISA Assay Kit
The kit’s reference number was 5201-16, and the lot# was DA314050802. The
kits came from Diagnostic Automation/Cortez Diagnostics, Inc. (Calabasas, CA, USA).
Materials also required that did not come in the kits were disposable tips, pipettors of 25
uL and 100 uL, a microwell reader, and deionized water for blanks.
The CEA quantitative test kit is based on a solid phase enzyme-linked
immunosorbent assay with a detection range of 0-120 ng/mL. The test requires 50 uL of
serum, and it performs with a specificity of 95% and sensitivity of 1.0 ng/mL. The assay
system utilizes one monoclonal anti-CEA antibody for solid phase immobilization and
another mouse monoclonal anti-CEA antibody in the antibody-enzyme conjugate
solution. The standards and the testing specimens were added to the CEA antibody
coated microtiter wells. The CEA antibody labeled with horseradish peroxidase
(conjugate) was added. If human CEA was present in the specimen, it would combine
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with the antibody on the well and the antibody conjugate. The solution was then
washed with the wash buffer, which removed any unbound conjugate. The TMB solution
was then added. A colorimetric reaction occurs whose final intensity reveals the
concentration of CEA present.
When preparing the assay, all the reagents and samples were brought to room
temperature (~25ºC) and gently mixed. The wash buffer was prepared by adding 15 mL
of the washing buffer into 735 mL of distilled water in a large flask. The mixture was
capped and inverted several times to mix. The wash buffer was then poured into the
solution bottle. Blanks (deionized water), calibration solutions, and controls were run in
duplicate in the first 14 wells of each plate. The remaining wells contained serum
samples and extra controls. A data sheet was kept to identify samples, calibrators, and
controls with their locations. The procedure is outlined in figure 1 as follows.
Figure 1
CEA ELISA Assay Kit Procedure
1. Secure the desired number of coated wells in the holder.
2. Dispense 50 uL of standard, specimens, and controls into appropriate wells.
3. Dispense 100 uL of enzyme conjugate reagent to each well.
4. Thoroughly mix for 10 seconds. It is very important to have complete mixing in
this step.
5. Incubate at room temperature (18-22ºC) for 60 minutes.
6. Remove the incubation mixture by emptying plate content into a waste container.
7. Rinse and empty the microtiter wells 5 times with washing buffer (1X).
8. Strike the wells sharply onto absorbent paper or paper towels to remove all
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residual water droplets.
9. Dispense 100 uL of TMB substrate into each well. Gently mix for 5 seconds.
10. Incubate at room temperature for 20 minutes.
11. Stop the reaction by adding 100 uL of stop solution to each well.
12. Gently fix for 30 seconds to ensure that the blue color completely changes to
yellow.
13. Read optial density at 450 nm with a microtiter plate reader within 15 minutes
NSE ELISA Assay Kit
The kit’s reference number was 6334-16, and the lot# was DA314050901. The kit came
from Diagnostic Automation/Cortez Diagnostics, Inc. Materials also required that did
not come in the kit were disposable tips, pipettors of 25 uL and 100 uL, a microwell
reader, and deionized water for blanks.
The NSE quantitative test kit is based on a solid phase enzyme-linked
immunosorbent assay with a detection range of 0-120 ng/mL. The test requires 15 uL of
serum, and it performs with a specificity of 98.7% and sensitivity of 1.5 ng/mL (as
recorded by Diagnostic Automation/Cortez Diagnostics, Inc.). The assay system utilizes
one monoclonal anti-NSE antibody for solid phase immobilization and another
monoclonal anti-NSE antibody in the antibody-enzyme conjugate solution. The
standards and the testing specimens were added to the antibody coated microtiter wells. If
human NSE was present in the specimen, then it would combine with the antibody on the
well and the antibody conjugate. The solution was then washed with the wash buffer,
which removed any unbound conjugate. The amount of bound peroxidase is proportional
to the concentration of the NSE present in each sample. After addition of the substrate
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and chromogen, the intensity of blue color developed in proportion to the concentration
of NSE antigen in the samples.
When preparing the assay, all the reagents and samples were brought to room
temperature (~25ºC) and gently mixed. The wash buffer was prepared by adding 15 mL
of the washing buffer into 735 mL of distilled water in a large flask. The mixture was
capped and inverted several times to mix. The wash buffer was then poured into the
solution bottle. Blanks (deionized water), calibration solutions, and controls were run in
duplicate in the first 14 wells of each kit. The remaining wells contained serum samples
and extra controls. A data sheet was kept to identify samples, calibrators, and controls
with their locations. The procedure is outlined in figure 2 as follows.
Figure 2
NSE ELIA Assay Kit Procedure
1. Secure the desired number of coated wells in the holder.
2. Dispense 25 uL of standard, specimens, and controls into appropriate wells.
3. Dispense 100 uL of sample diluent into each well.
4. Thoroughly mix for 10 seconds. It is very important to have complete mixing in
this step.
5. Incubate at room temperature (18-22ºC) for 30 minutes.
6. Remove the incubation mixture by emptying plate content into a waste container.
7. Rinse and empty the microtiter wells 5 times with washing buffer (1X).
8. Strike the wells sharply onto absorbent paper or paper towels to remove all
residual water droplets.
9. Dispense 100 uL of Enzyme Conjugate Reagent into each well. Gently mix for 5
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seconds.
10. Incubate at room temperature for 30 minutes.
11. Remove the incubation mixture by flicking plate contents into a waste container.
12. Rinse and flick the microtiter wells 4 times with washing buffer (1X).
13. Strike the wells sharply onto absorbent paper to remove residual water droplets.
14. Dispense 100 uL of TMB substrate into each well. Gentle mix for 5 seconds.
15. Incubate at room temperature for 20 minutes.
16. Stop the reaction by adding 100 uL of stop solution to each well.
17. Gently fix for 30 seconds to ensure that the blue color completely changes to
yellow.
18. Read optical density at 450 nm with a microtiter plate reader within 30 minutes.
CYFRA 21-1 ELISA Assay Kit
The kit’s number was 211-10, and the lot# was 34112:1. The kits came from
Fujirebio Diagnostic, Inc (Seguin, TX, USA). Materials also required that did not come
in the kits were disposable tips, pipettors of 25 uL and 100 uL, a microwell reader, and
deionized water for blanks.
The CYFRA 21-1 quantitative test kit is based on a solid phase enzyme-linked
immunosorbent assay with a detection range of 0.5-50 ng/mL. The test sensitivity and
specificity can be seen below in table 2. The assay system utilizes one monoclonal antiCYFRA 21-1 antibody for solid phase immobilization and another mouse monoclonal
anti-CYFRA 21-1 antibody in the antibody-enzyme conjugate solution. The standards
and the testing specimens were added to the CYFRA 21-1 antibody coated microtiter
wells. The CYFRA 21-1 antibody labeled with horseradish peroxidase (conjugate) was
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added. If human CYFRA 21-1 was present in the specimen, then it would combine
with the antibody on the well and the antibody conjugate. The solution was then washed
with the wash buffer, which removed any unbound conjugate. The TMB solution was
then added. A colorimetric reaction occurs whose final intensity reveals the
concentration of CYFRA 21-1 present.
When preparing the assay, all the reagents and samples were brought to room
temperature (~25ºC) and gently mixed. The wash buffer was prepared by adding 50 mL
of the washing buffer into 1200 mL of distilled water in a large flask. The mixture was
capped and inverted several times to mix. The wash buffer was then poured into the
solution bottle. Blanks (deionized water), calibration solutions, and controls were run in
duplicate in the first 14 wells of each kit. The remaining wells contained serum samples
and extra controls. A data sheet was kept to identify samples, calibrators, and controls
with their locations. The procedure is outlined in figure 3 as follows.
Figure 3
CYFRA 21-1 ELISA Assay Kit Procedure
1. Prepare CYFRA 21-1 calibrators and controls by adding 1 mL of distilled water
to each vial. Allow to stand for at least 15 minutes.
2. Prepare wash solution by adding 50 mL of wash concentration to 1200 mL of
distilled water.
3. Prepare antibody solution by mixing 50 uL of tracer, HRP anti-CYFRA 21-1 with
1 mL of Biotin Anti-CYFRA 21-1 per strip.
4. Wash each well once with the wash solution.
5. Add calibrators’ controls and samples by putting 50 uL in each well. The mixing
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of samples using electric vibration mixers must be limited to a maximum of 1
second.
6. Add antibody solution- 100 uL in each well.
7. Incubate for 1 hour.
8. Wash each well 6 times with wash solution.
9. Add TMB HRP- substrate- 100 uL in each well.
10. Incubate for 30 minutes.
11. Read absorbance at 620 nm.
Table 2
Specificity and Sensitivity per % concentration
% increase in CYFRA 21-1 % Sensitivity
Concentration
30
52.9

% Specificity

40

48.2

85.6

50

45.9

87.3

60

44.7

88.2

70

43.5

89.5

Results

84.3
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Over the course of the project, there were quality control samples incorporated
into the assays to determine within-run and between-run precision (Table 3-4). NSE,
CEA, and CYFRA 21-1 all had controls run to determine the precision. These controls
had a known amount of antigen incorporated into the sample. This determined if the
assay was running correctly. The within-run precision was excellent, being under 10%
for the percent coefficient of variation for NSE at 2.78%, CYFRA 21-1 at 6.27%, and
CEA at 6.78%. The between run precision was also excellent for the percent coefficient
of variation of CYFRA 21-1 at 6.16% and CEA at 8.33%. The between run precision
was good for NSE with a percent coefficient of variation of 15.37%, being that it was still
under 20%.
Serial dilutions of patient samples were used to determine the linearity of the
assays (Table 5, Graph 1-3). These results indicate excellent linearity with R2 values
between 0.94 and 0.99.
The minimum concentration each assay was able to detect was determined by
calculating the analytical sensitivity (Table 6). The analytical sensitivity of NSE was
determined by analyzing 10 replicates and calculating the mean (+/-) two standard
deviations (𝑋𝑋� +/- 2SD). This revealed a range of 6.10-7.02. The ranges for CYFRA 21-1
and CEA were determined the same way. CYFRA 21-1 had a cut off value of 0.07,
determined by analyzing 20 replicates, and CEA had a cut off value of 0.70, also
determined by analyzing 20 replicates.
The normal reference intervals (𝑋𝑋� +/- 2SD) are the reference intervals that were

developed from healthy control subjects. The healthy control subjects were known to

have no disease. The normal reference intervals for each of the antigens studied can be
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seen in Table 7.
In determining the negative and positive patient results, the manufacturers’ cut off
values were used. Diagnostic sensitivities of 0.00% (NSE), 18.9% (CYFRA 21-1), and
22.37% (CEA) were obtained (Table 8). Diagnostic sensitivity is the proportion of
individuals with a disease who test positive for the disease. The higher the sensitivity the
better the test is. Diagnostic specificity is the proportion of individuals without the
disease who test negatively for the disease. Diagnostic specificities of 99.39% (NSE),
93.2% (CYFRA 21-1), and 80.43% (CEA) were obtained. Some other parameters that
can be evaluated are predictive value (+), predictive value (-), and percent efficiency.
Predictive value plus is the fraction of positive tests that are the true positives. Predictive
value minus is the fraction of negative tests that are true negatives. The percent
efficiency is the fraction of all test results that are either true positives or true negatives.
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Table 3
Within Run Assay Precision for NSE, CYFRA 21-1, and CEA
n

Mean

SD

%CV

NSE control

10

7.55 ng/mL

0.21

2.78

CYFRA 21-1 High Control

20

14.17 ng/mL

0.77

5.41

CYFRA 21-1 Low Control

20

4.41 ng/mL

0.28

6.27

CEA High Control

72

62.64 ng/mL

3.40

5.43

CEA Low control

76

4.44 ng/mL

0.37

8.33

Table 4
Between Run Precision for NSE, CYFRA 21-1, and CEA
n

Mean

SD

%CV

NSE Control

43

7.87 ng/mL

1.21

15.37

CYFRA 21-1 High Control

76

13.97 ng/mL

0.86

6.16

CYFRA 21-1 Low Control

78

5.45 ng/mL

0.86

6.16

CEA High Control

72

62.64 ng/mL

3.40

5.43

CEA Low Control

76

4.44 ng/mL

0.37

8.33
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Table 5
Assay Linearity for NSE, CYFRA 21-1, and CEA
Assay

R
squared

NSE

0.997

Cyfra 21-1

0.992

CEA

0.939

Table 6
Analytical Sensitivity for NSE, CYFRA 21-1, and CEA
n

Mean

SD

Range

NSE

10

6.56 ng/mL

0.23

6.10-7.02

CYFRA 21-1

20

0.01 ng/mL

0.03

0.00-0.07

CEA

20

0.00 ng/mL

0.35

0.00-0.70
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Table 7
Normal Reference Intervals for NSE, CYFRA 21-1, and CEA
N

Minimum

Maximum

Mean

SD

Range

NSE

174

3.62

8.45

6.61

1.31

3.99-9.23

CYFRA 21-1

189

0.00

82.9

2.21

9.36

0.00-20.93

CEA

204

0.00

16.10

2.40

2.63

0.00-7.66

Table 8
Predictive values for NSE, CYFRA 21-1, and CEA in 638 Patients
Sensitivity

Specificity

PV

PV (-

Efficiency

Cut-Off

(%)

(%)

(+)

)

(%)

(ng/mL)

(%)

(%)

NSE

0.00

99.39

0.00

87.12

86.65

15.01

CYFRA

18.9

93.2

28.0

89.1

84.0

1.82

22.37

80.43

13.39

88.45

73.5

5.01

21-1

CEA
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Graph 1
CEA Linearity Plot
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Graph 2
CYFRA 21-1 Linearity Plot
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Graph 3
NSE Linearity Plot
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Discussion
The analytical parameters for each of the three testing methods were adequate.
The normal reference interval for CYFRA 21-1 was dramatically higher than the
reference interval determined by the manufacturer. This is possibly due to geographic
location and the mix of healthy adult subjects tested. None of the diagnostic sensitivities
were desirable, but of the three examined, CEA was the best predictor of the disease.
The sensitivity would be the most important test result because it demonstrates the ability
of the assay to diagnose the presence of disease. The diagnostic specificities obtained for
the true negatives were excellent, with NSE having the best specificity at 99.39%. This
result greatly differed from the 0% found for the sensitivity of NSE. Mathematically,
because of the high percent efficiency of NSE at 86.65%, it appeared to be the best
predictor of the disease, but a high sensitivity is what is desired. The “cutoff” points used
for all three of the markers were those of the manufacturers’. By adjusting the “cutoff”
points one could raise the sensitivity, but the specificity would be lowered. For a more
accurate study for a given environment and patient mixes, one could use the normal
reference intervals as the “cut-off” points.
A strong point of this study is the small number of people that were directly
involved in the testing of the samples. This keeps the relative amount of human error
minimal. The age of some of the samples is a possible weakness due to potential sample
degradation at minus 20ºC. To improve the accuracy of the study, a larger number of
subjects could be obtained, and the subjects could be acquired from multiple geographic
regions. The samples should also be fresh and only thawed once when tested.
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Conclusion
From the data collected, CEA was the most sensitive screen for predicting lung
cancer. NSE was the most specific, and CYFRA 21-1 had the next highest sensitivity
and specificity. The highest sensitivity is the most important part of a test because it
predicts the true positives. CEA, the best predictor of the disease, is one of the oldest
tumor markers. It is common in determining other cancers such as colorectal cancer. The
CEA subgroup members are cell membrane associated and show a complex expression
pattern in normal and cancerous tissues (Hammarstrom, 1999). This is a strong point for
the tumor marker because it has the ability to track cancer formation in different areas of
the body in different organs. The object of a tumor marker is a non-invasive test to track
a patient’s health after recovering from cancer. Physicians and researchers are always
seeking noninvasive tests like tumor markers to make early diagnosis and track a
patient’s recovery. The hypothesis that CYFRA 21-1 would be the most accurate and
specific predictor of the disease was rejected. CYFRA 21-1is an independent prognostic
factor, though, that is useful in the earlier stages of squamous cell lung cancer (SQC)
(Kulpa, 2002). CYFRA 21-1 was not as sensitive to lung cancer for predicting the true
positives, and since the object of the game is diagnosing a positive occurrence of the
disease, it was not the best predictor.
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